Decision-making procedures and information sharing for the Biosafety Clearing-House2000-12-15 AOSIS
Topic: Sustainable Development
Statement by the delegation of Jamaica on decision-making procedures Thank you Mr. Chairman. The Small Island Developing States have considered this issue in a preliminary manner. We have noted that the experience in other relevant conventions demonstrates the need for capacity building as being vital to their effective implementation. It is clear that for the Cartagena Protocol there will also be a need for procedures specifically designed to assist Parties with decision making in different cases, namely that of import, export or domestic use of LMOs. Case studies and further workshops, including dissemination of information on these efforts are deemed by our group to be important elements. The Secretariat paper is a valuable starting point for us to consider further. Our delegations will need more time to come to a final decision on this matter, but we support the general approach taken by the Secretariat. Thank you. Statement by the delegation of Jamaica on information sharing Mr. Chairman, I have the honor to speak on behalf of the 43 Members and Observers of the Alliance of Small Island States – AOSIS. Our delegations will be speaking as a group at this first meeting of the Intergovernmental Committee for the Cartagena Protocol, as well as at the future sessions. Our group held a preparatory workshop last week in Saint Kitts and Nevis. We thoroughly discussed all issues on the agenda of this meeting. My delegation will the spokesperson for the Alliance of Small Island States in this working group, and I wish to share with other delegations some of our views on information sharing. The importance of the Biosafety Clearing-House to our members is viewed as more than central, given its expected role in assisting Small Island Developing States in capacity building. We think that the word “critical” should be substituted. As SIDS have very limited resources, it is important for our countries to avoid duplication. We therefore wish to see all relevant organizations cooperating, and overlaps to be avoided. In this regard, there is a need for the ICCP to identify which international organizations are relevant to the designation of pharmaceutical LMOs for human use. We have attempted to elaborate what the respective roles of the CHM and BCH should be in respect of the special needs of SIDS, but have not been able to at the present time. In order to reach a clear consensus on this matter, we have agreed to discuss it in further detail as part of the ongoing work of Small Island Developing States on biosafety. Let me just raise one general concern that was raised, namely whether there was a risk of the information provided to the BCH being ‘biased’. Developed countries which have the capacity to produce scientific and technical information, may choose not to submit certain information (or their nationals may not make such information available) regarding LMOs that a party (or its national) is intending to export in the future. Finally, Mr. Chairman, we are grateful for the opportunity to come back with further textual proposals in light of the discussion here. Let me only mention that we wish to adhere strictly to the text of the protocol, and that the terminology which recognizes the special needs of the least developed and small island developing States among them must be retained in our decision. Thank you.
Sub Topic: Cross-cutting
Meeting: Intergovernmental Committee for the Cartagena Protocol on Biosafety (ICCP)